We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Autoantibody against Septin-3 Discovered in Neurological Disease

By LabMedica International staff writers
Posted on 27 Apr 2023

Septins are cytoskeletal proteins that play multiple roles in cell division, cellular polarization, morphogenesis, and membrane trafficking. Septin-5 and septin-7 are already known target antigens of autoantibodies in neurological diseases. Now, scientists have discovered autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia.

In a collaborative study between EUROIMMUN (Lübeck, Germany), the University of Heidelberg (Heidelberg, Germany), and other German clinics, researchers analyzed three patient sera with similar immunofluorescence staining patterns on cerebellar and hippocampal sections. They identified septin-3, -5, -6, -7, and -11 as candidate target antigens using immunoprecipitation and mass spectrometry. These proteins were then expressed recombinantly in HEK293 cells either individually, as complexes, or in combinations missing individual septins. The cells were used in recombinant-cell indirect immunofluorescence assays (RC-IIFA) to detect corresponding autoantibodies.


Image: septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes (Photo courtesy of EUROIMMUN)
Image: septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes (Photo courtesy of EUROIMMUN)

The three patient sera reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of the control sera did. Different septin combinations confirmed the autoantibodies' specificity for septin-3. In RC-IIFA analyses, patient sera reacted only with cells expressing septin-3, either individually or in complexes. The specificity was further verified by eliminating tissue IIFA reactivity through prior neutralization of autoantibodies with recombinant septin-3. All three patients presented with progressive cerebellar syndrome and responded poorly to immunotherapy. All had cancer (2 melanomas and 1 small-cell lung cancer). Expression of septin-3 was demonstrated in resected tumor tissue available from one patient.

The authors concluded that septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Due to the different clinical phenotypes reported in patients with anti-septin-3, -5, and -7 autoimmunity, these autoantibodies may serve as markers for different clinical presentations. As a result, septin-3 IgG-associated autoimmune cerebellar ataxia might represent a new paraneoplastic neurological syndrome (PNS). The suggested strategy for determining anti-septin autoantibodies is RC-IIFA with the complex septin-3/5/6/7/11 as a screening tool to investigate serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single antigens.

Related Links:
EUROIMMUN 
University of Heidelberg


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Multi-Function Pipetting Platform
apricot PP5

Latest Molecular Diagnostics News

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis



Sekisui Diagnostics UK Ltd.